Ursula A. Matulonis, MD, discusses the results of the phase 3 SORAYA trial in platinum-resistant ovarian cancer.
Ursula A. Matulonis, MD, physician chief, Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Brock-Wilson Family Chair, institute physician, professor of Medicine, Harvard Medical School, discusses the results of the phase 3 SORAYA trial (NCT04296890) in platinum-resistant ovarian cancer.
The antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) features a folate receptor α–binding antibody, plus a cleavable linker to maytansinoid DM4, a potent anti-tubulin agent, Matulonis says. This agent was utilized in the SORAYA trial in patients withplatinum-resistant ovarian cancer who all had high-grade serous disease and up to 3 prior lines of bevacizumab (Avastin), Matulonis explains.
The primary end point of the trial was overall response rate (ORR) of at least 24%, which would have doubled the known ORR of 12% for single-agent chemotherapy in platinum-resistant ovarian cancer, Matulonis says. However, mirvetuximab soravtansine achieved a confirmed ORR of 32.4%, including 5 complete responses and 29 partial responses, Matulonis concludes.